Description

PT-141 — 10 mg

Clinician-Guided Support for Sexual Health

PT-141, also known as bremelanotide, is a melanocortin receptor agonist that acts on pathways in the central nervous system involved in sexual desire and arousal. It is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women when the condition is not caused by a medical or psychiatric condition, relationship difficulties, or the effects of another medication or substance.

Unlike medications that primarily affect blood flow, bremelanotide works through the nervous system and is intended for use before anticipated sexual activity. It is not approved for enhancing sexual performance in men or women or for treating erectile dysfunction.

Treatment requires an appropriate medical evaluation to determine whether bremelanotide is suitable. A qualified healthcare professional can review your medical history, medications, cardiovascular health, and treatment goals before prescribing.

Treatment eligibility is determined individually following an appropriate clinical evaluation.